The detection of high-risk human papilloma virus (HPV) allows us to predict the presence and future development of cervical intraepithelial neoplasia. The aim of this study was to evaluate the efficacy and diagnostic performance of hybrid capture (HC) II and oligonucleotide microarray (HPV DNA chip) in detecting high risk HPV.

Cytologic study, HC II, HPV DNA chip test and pathologic study (punch biopsy, cone biopsy or hysterectomy) were performed on 102 patients. The screening performance was evaluated, such as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

HPV tests were performed to detect high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). The sensitivity of each test to detect low grade cervical intraepithelial neoplasia (LGCIN), high grade cervical intraepithelial neoplasia (HGCIN) and invasive cancer was 65.7% in HC II and 85.7% in oligonucleotide microarray. The combination of each test and cytologic study resulted in higher sensitivities, 90.0% in HC II and 95.5% in oligonucleotide. For patients with HGCIN and invasive cancer, the sensitivity was 71.7% in HC II and 86.8% in oligonucleotide microarray. In cases of multiple HPV subtype infection, the PPV of DNA chip was 89.5%.

DNA chip test was more sensitive in detecting women with CIN lesion/invasive cancer and high risk HPV infection than HC II in a single test but no significant difference is found when combined with cytologic study. There was a highly significant correlation between multiple HPV subtype infection and CIN lesion/invasive cancer.